1. Home
  2. DKL vs NVCR Comparison

DKL vs NVCR Comparison

Compare DKL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKL

Delek Logistics Partners

HOLD

Current Price

$44.75

Market Cap

2.4B

Sector

Energy

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$13.35

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKL
NVCR
Founded
2012
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Natural Gas Distribution
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
1.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
DKL
NVCR
Price
$44.75
$13.35
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$45.50
$28.42
AVG Volume (30 Days)
50.5K
1.7M
Earning Date
11-07-2025
10-30-2025
Dividend Yield
10.01%
N/A
EPS Growth
9.17
N/A
EPS
3.09
N/A
Revenue
$967,420,000.00
$642,269,000.00
Revenue This Year
$12.80
$9.75
Revenue Next Year
$11.50
$5.62
P/E Ratio
$14.47
N/A
Revenue Growth
N/A
11.17
52 Week Low
$34.59
$10.70
52 Week High
$48.00
$34.13

Technical Indicators

Market Signals
Indicator
DKL
NVCR
Relative Strength Index (RSI) 46.04 60.37
Support Level $44.50 $10.79
Resistance Level $46.81 $13.94
Average True Range (ATR) 1.04 0.61
MACD -0.12 0.22
Stochastic Oscillator 26.69 80.48

Price Performance

Historical Comparison
DKL
NVCR

About DKL Delek Logistics Partners

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: